الفهرس 
COVID-19Only 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Background: The ongoing pandemic of coronavirus disease 2019 (COVID-19) poses several challenges to clinicians. Serum chemokine levels such as MCP-1and IL-6 are elevated in patients with COVID-19, and they are even higher in those who required intensive-care unit (ICU) admission, suggesting a relationship between these chemokines and both lung damage and disease severity.
Aim of the study: To evaluate the level of monocytic chemotactic protein-1 (MCP-1) in mild, severe and post COVID-19 patients to explore the correlation between (MCP-1) and the severity of the disease. The findings of this study will add to our understanding the role of MCP-1 in diagnosis of COVID-19 patients and the relation between MCP-1 level and the severity of the disease, providing potential diagnostic, prognostic and even therabeutic strategies for COVID-19 patients using MCP-1 as a marker.
Patients and Methods: This case control study was conducted as a collaborate work between the Clinical Pathology Department and the Intensive Care Units at Ain Shams University Hospital between March 2021 and November 2021. The study included 87 patients diagnosed as COVID-19 positive by PCR. Patients were subdivided according to the clinical condition into severe group (n = 45) (51.8 %), mild group (n = 22) (25.2%) and convalescent group (n= 20) (23%) as well as 60 age and gender matched healthy subjects were recruited as a control group.
Results: Our results stated that MCP-1 can differentiate the current cases (either mild or severe) from the convalescent cases as well as the other lab markers (CRP,D-Dimer and ferritin). However, according to our results, MCP-1 had even more sensitivity and specificity than other lab markers (CRP, D-Dimer and ferritin).
Conclusion: This study added to our understanding the role of MCP-1 in diagnosis of COVID-19 patients and the relation between MCP-1 level and the severity of the disease, providing potential diagnostic, prognostic and therapeutic strategies for COVID-19 patients using MCP-1 as a marker. However, further research is needed about the advantages of MCP-1 over the other known markers in the diagnosis and the prognosis of COVID.